How PBM Data Analytics Is Changing Pharmacy Benefits

PBM data analytics is changing how brokers, TPAs, employers, and pharmacy benefit managers evaluate and manage pharmacy benefits. By connecting claims, eligibility, pricing, formulary, and clinical information, stakeholders can identify cost concerns earlier, provide more relevant member support, and improve prescribing decisions at the point of care.

The value comes from shortening the distance between information and action.

For years, much of pharmacy benefit reporting has focused on explaining what already happened. The prescription was written, the claim was processed, the member paid, and the plan absorbed the cost, with a report arriving weeks or months later.

Retrospective reporting remains useful, but it cannot change a decision that has already been made. Data becomes more powerful when it reaches a broker, plan sponsor, member, or prescriber while there is still an opportunity to respond.

How is data changing pharmacy benefit management?

Better use of pharmacy data allows stakeholders to manage the benefit throughout the year instead of concentrating most of their attention around renewal.

Claims data can reveal where plan spending is increasing. Formulary information can show whether members and prescribers have access to cost-effective options. Eligibility and utilization data can help identify members who may need support before they stop taking a medication or encounter an unexpected expense.

This creates a more active model of benefit management.

A broker may see that a small group of medications is driving a disproportionate share of plan spending. An employer may discover that members are being directed toward a higher-cost pharmacy channel. A TPA may identify delays or inconsistencies that are affecting the member experience.

Those findings can support targeted changes without requiring every employer to follow the same path. Some plans may need additional technology, clinical oversight, or member support around the current PBM. Others may determine that broader change is appropriate.

The data helps define the size of the problem before stakeholders choose the solution.

Where is PBM data analytics making the biggest impact?

PBM data analytics is having its greatest effect in areas where timing influences the decision. The most important opportunities tend to appear in plan management, member support, and prescribing.

Earlier identification of cost and utilization concerns

Traditional reports can show which medications drove spending during the previous quarter or plan year. More timely data can help stakeholders recognize a developing issue before it becomes embedded in the plan.

For example, an employer may see increased use of a high-cost therapy, a change in prescribing patterns, or unexpected movement toward a particular pharmacy channel. These patterns often connect to broader factors shaping pharmacy spend, including formulary design, specialty growth, pricing arrangements, and limited access to timely information.

Those findings can prompt a review of formulary placement, clinical criteria, network design, or member communication.

This does not mean every increase requires intervention; utilization may rise for valid clinical reasons. The goal is to understand what is happening early enough to ask informed questions.

Brokers also gain a stronger foundation for vendor discussions. Instead of reviewing guarantees in isolation, they can examine how pricing, utilization management, pharmacy access, and member behavior interact.

More relevant member support

Members rarely experience the pharmacy benefit through a quarterly report. They experience it when a prescription is denied, when a medication costs more than expected, or when they are unsure which pharmacy to use.

Member-level data can make support more relevant to those moments.

Consider someone beginning a specialty medication. A generic welcome message may explain the benefit in broad terms. A more informed experience could address the approval process, expected cost, available pharmacy options, and support resources associated with that therapy.

Refill patterns may also indicate that a member is having difficulty remaining on treatment. Outreach can help determine whether affordability, side effects, access, or confusion is contributing to the problem.

Rescription combines current claims information with personal support from its Care Guide team, helping members understand medication access, pharmacy options, costs, and next steps.

Personalization should remain purposeful. Members do not need a steady stream of automated messages simply because the data makes them possible. They need useful information tied to a decision they are facing.

Better decisions at the point of care

Some of the most consequential pharmacy decisions happen before a claim reaches the PBM.

Real-time prescription benefit tools can provide patient-specific information about coverage, estimated out-of-pocket cost, prior authorization requirements, and potential alternatives while the prescriber is selecting a medication.

This gives the provider and patient an opportunity to discuss coverage and cost before the prescription reaches the pharmacy counter.

The federal HTI-4 final rule introduced new health IT certification criteria related to electronic prescribing, prior authorization, and real-time prescription benefit information. The rule supports greater exchange of cost, coverage, clinical, and administrative information among providers, payers, and other healthcare organizations.

Peer-reviewed research on real-time prescription benefit tools has associated their use with greater medication adherence, increased selection of cost-effective generic drugs, and lower costs for members and health plans. Adoption remains uneven, but the direction is important.

Pharmacy benefit information is beginning to influence the prescribing process rather than simply documenting its financial result.

How does better PBM data affect stakeholders?

The value of pharmacy benefit data differs depending on who is using it.

Brokers can use detailed plan information to evaluate vendors, question assumptions, and bring more substance to renewal discussions. Data can also help them determine whether the employer needs targeted support around the current arrangement or should consider a broader change.

TPAs benefit when pharmacy information can be viewed alongside the other parts of the health plan. That broader perspective can reveal connections between medication use, care patterns, member needs, and total plan spending.

Employers gain a more complete view of how the pharmacy benefit is performing. They can examine where plan dollars are going, whether members are receiving appropriate support, and how the current structure aligns with their financial and workforce priorities.

Members benefit when information reduces surprises and helps them navigate the benefit. A lower-cost alternative provides little value when the member learns about it after abandoning the prescription.

Providers gain access to benefit information that can support more informed prescribing decisions. PBMs and other vendors face a more specific standard for performance because their work can be evaluated using timely and consistent information.

Data does not remove the competing interests within the pharmacy system. It makes those interests easier to examine.

What should brokers and employers evaluate?

As it has been discussed so far, more data does not automatically create a better pharmacy benefit. Brokers and employers should evaluate whether the information is current, understandable, and connected to a defined process for action.

Important questions include:

• How frequently are claims, pricing, and utilization data updated?

• Can the employer access claim-level information, and are key fields consistently defined?

• Can identified issues lead to member, provider, clinical, or plan-level interventions?

• Can the technology work alongside the current PBM?

• Who is responsible for reviewing findings and determining the next step?

• How are data accuracy, privacy, and security managed?

These questions help separate a useful operating capability from a reporting tool that generates more material for someone to review later.

A technically advanced dashboard can still leave a plan sponsor with the same questions it had last quarter. The platform becomes valuable when the information leads to a decision, intervention, or productive vendor conversation.

What challenges limit the value of PBM data?

The pharmacy benefit industry produces enormous amounts of information, but several barriers can prevent stakeholders from using it effectively.

Inconsistent definitions and data quality

Different organizations may use the same field to represent different payments, time periods, or parts of the pharmacy transaction.

A 2024 review by the U.S. Department of Health and Human Services Office of Inspector General found that states did not consistently define or validate paid-amount data for Medicaid managed care drug claims. The agency warned that inconsistent reporting could weaken efforts to understand spending and oversee program finances.

Although the report focused on Medicaid, the broader issue applies across the pharmacy industry. Analysis becomes less reliable when stakeholders do not share common definitions.

Employers and brokers should understand how fields are calculated, whether the data has been validated, and which parts of the transaction may be excluded.

Limited interoperability

Pharmacy information often sits across multiple systems, including the PBM, health plan, pharmacy, provider, and member-support platforms.

A federal pharmacy interoperability task force found that electronic prescribing has advanced considerably, while comparatively little progress has been made in exchanging information among all the organizations involved in medication management.

When systems cannot exchange information effectively, stakeholders may receive an incomplete or delayed picture of the member and the plan.

Interoperability requires more than transferring files. The receiving system must be able to interpret the information and place it into a workflow where someone can use it.

Privacy, security, and governance

More detailed information creates additional responsibility.

Employers need appropriate access to information about their plans, while individual health data requires careful protection. Vendors should explain how data is stored, who can view it, and how analytical models reach their recommendations.

These requirements should be addressed during contracting and implementation. Data ownership, access rights, timing, validation, and permitted uses should not become renewal-season surprises.

No defined process for action

A plan can have accurate, timely information and still fail to improve performance when no one is responsible for acting on it.

Technology may identify a high-cost trend, an adherence concern, or an inefficient pharmacy channel. Someone must review the findings, understand the surrounding context, and decide what happens next.

The operating model is as important as the analytical platform.

Can PBM data tools work with an existing PBM?

Yes. Employers do not always need to replace their PBM to gain better access to information or improve plan performance.

Independent technology, clinical oversight, member-support services, and pharmacy navigation can often be added around an existing arrangement. This allows the employer and broker to address a specific concern without forcing a full transition.

Rescription’s pharmacy benefits technology provides real-time claims visibility, drug pricing information, and tools for clients, members, and Care Guides. These capabilities can support a current PBM arrangement or play a role in a wider change.

In some cases, the data may reveal structural problems that cannot be corrected through a limited intervention. Those findings can help stakeholders prepare for a broader PBM evaluation.

Rescription’s approach reflects this range of needs. The work begins by identifying where the current arrangement is underperforming and how extensive the response should be. The appropriate solution may strengthen the existing model or support a wider transition.

Starting with the data reduces the risk of selecting a predetermined answer before the problem is fully understood.

Frequently asked questions about PBM data analytics

What data should employers receive from their PBM?

Employers should have access to timely claims, pricing, utilization, formulary, rebate, and pharmacy-channel information. Key fields should use consistent definitions, and the employer should understand how payments and financial guarantees are calculated.

How can PBM data analytics reduce pharmacy costs?

PBM data analytics can identify pricing variation, changes in utilization, inefficient pharmacy channels, and opportunities for clinical intervention. Earlier identification gives stakeholders more time to review the issue and choose an appropriate response.

How can pharmacy data improve the member experience?

Member-level information can support more relevant communication about coverage, cost, pharmacy options, prior authorization, and available assistance. Outreach is most useful when it addresses a specific issue the member is likely to encounter.

What is real-time prescription benefit information?

Real-time prescription benefit information gives prescribers patient-specific details about coverage, estimated cost, and possible alternatives while they are selecting a medication. This can help address coverage or affordability concerns before the patient reaches the pharmacy.

Does more data guarantee better plan performance?

No. Employers also need reliable definitions, timely access, responsible governance, and a defined process for reviewing findings. The information must connect to people who can evaluate it and take appropriate action.

Turning PBM data analytics into better decisions

The next phase of PBM data analytics will be measured by the decisions it improves.

The most useful information reaches stakeholders while there is still time to respond. It helps a broker prepare a stronger recommendation, allows an employer to intervene before costs accelerate, gives a member support at a useful moment, or helps a prescriber consider an appropriate alternative.

In Rescription’s work with brokers and self-funded employers, the most valuable data is rarely the largest dataset. It is the information that helps someone decide what to do next.

Technology can identify a concern quickly, but effective pharmacy benefit management still requires judgment, follow-through, and accountability. When those pieces work together, data moves beyond reporting and becomes part of how the benefit is managed.

Learn how Rescription can help strengthen your current PBM strategy or support a broader change.

Sources

Five Factors Shaping Pharmacy Spend, Rescription

HTI-4 Final Rule, Office of the National Coordinator for Health Information Technology

Real-Time Prescription Benefit Tools and Their Impact on Medication Cost and Adherence, PubMed Central

Medicaid Managed Care: States Do Not Consistently Define or Validate Paid Amount Data for Drug Claims, U.S. Department of Health and Human Services Office of Inspector General

Pharmacy Interoperability and Emerging Therapeutics Task Force Recommendations Report, Health Information Technology Advisory Committee